Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04775797
Status:
TERMINATED
Last Update Posted:
2022-11-21
First Post:
2021-02-24
Brief Title:
Safety Tolerability and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
Sponsor:
Arbutus Biopharma Corporation
Organization:
Arbutus Biopharma Corporation
Study Overview
Official Title:
A Double-Blind Randomized Placebo-Controlled Single and Multiple Dose Study Evaluating the Safety Tolerability and Pharmacokinetics of AB-836 an HBV Capsid Inhibitor in Healthy Subjects and Subjects With Chronic HBV Infection
Status:
TERMINATED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Safety
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This three-part Phase 1 protocol will be the first clinical study of AB-836 Parts 1 and 2ab will be a Phase 1a SADMAD of AB-836 in healthy adult subjects Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B CHB subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None